Monday, December 31, 2018

Shilpa Medicare gets USFDA nod for cancer treatment injection

Shilpa Medicare gets USFDA nod for cancer treatment injection The company has received US Food and Drug Administration (USFDA) approval for its ANDA Irinotecan HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa Medicare said in a BSE filing.

from Moneycontrol Business News http://bit.ly/2QeZD2x
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

IREDA shares rise 1.1% as board announces meeting date for fund raise via QIP

IREDA shares rose by 1.1% to Rs 209.50 on news of a board meeting set for January 23, 2025, to approve fund-raising via Qualified Institutio...